Given that both TNF and IL1 antagonists are commonly used clinically to treat rheumatoid arthritis and autoimmune diseases, and have been confirmed to be safe, we speculate that we might able to use these FDA-approved TNF/IL1 antagonists and NF-κB inhibitors to evaluate our novel treatment approach in AML patients. The gene discussed is IL1A; the disease is acute myeloid leukemia.